A61P 27 - Drugs for disorders of the senses

Patents for A61P 27 - Drugs for disorders of the senses (53,017)
11/2009
11/11/2009	EP2116258A1 Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
11/11/2009	EP2114913A1 Thiophene derivatives useful as ocular hypotensive agents
11/11/2009	EP2114870A1 Synthetic ion channels
11/11/2009	EP2114411A2 Composition and method for protecting mitochondria
11/11/2009	EP2114398A1 Isosorbide mononitrate derivatives for the treatment of ocular hypertension
11/11/2009	EP2114395A2 Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof
11/11/2009	EP2114327A1 Methods and systems of treating age-related macular degeneration
11/11/2009	EP1603541B1 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
11/11/2009	EP1575964B1 N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists
11/11/2009	EP1557407B1 Novel alpha-ketoamide derivatives and use thereof
11/11/2009	EP1397351B1 Pyrimidine, triazine and pyrazine derivatives as glutamate receptors
11/11/2009	EP1191943B1 Anti-allergic peptides
11/11/2009	CN101575365A Antiviral protein and preparation method and application thereof
11/11/2009	CN101575341A Amidocyanogen amido xanthone pyridine derivant, and preparation method and application thereof
11/11/2009	CN101574520A Methods of administering anti-TNF alpha antibodies
11/11/2009	CN100558899C Growth hormone fusion protein
11/11/2009	CN100558724C Sulphonic acid amide for regulating bast peptide activity and derivative thereof
11/11/2009	CN100558712C Therapeutic molecules and methods-1
11/11/2009	CN100558410C Nucleic acids, polypeptides, and methods for modulating apoptosis
11/11/2009	CN100558364C Combination of brimonidine and timolol for topical ophthalmic use
11/11/2009	CN100558360C Amelioration of macular degeneration and other ophthalmic diseases
11/11/2009	CN100558346C Chinese medicinal preparation for statis moving hemostatis, swell dispersing pain stopping and its preparation method
11/10/2009	US7615573 Via amino ceramide-like compounds; lowering glycosphingolipid concentrations; Fabry's disease, Gaucher's disease
11/10/2009	US7615564 Such as N5-[1-(2-chlorobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolylamine; Rho kinase inhibitors; hypertension, asthma, angina pectoris, cerebrovascular contraction, peripheral circulatory disorder, threatened premature birth, glaucoma, vision disorders, autoimmune diseases, chronic renal failure
11/10/2009	US7615553 E.g., N,N-dimethyl,((5-(hydroxyaminocarbonyl)pyrimidin-2-yl)(piperazin-1,4-ylene)sulfonamide; bioavailability; oral administration; metabolic stability; side effect reduction; psoriasis; anticarcinogenic -proliferative, -arthritic, -inflammatory agent; gene therapy; genetic transcription potentiation
11/10/2009	US7615229 useful in inducing a protective immune response against NTHi in an immunized human
11/10/2009	US7615207 Methods for treating irritable bowel syndrome
11/10/2009	CA2481482C Tropane derivatives as ccr5 modulators
11/10/2009	CA2459930C Method of treating middle ear infections
11/10/2009	CA2457952C Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h) one derivatives for neurodegenerative disorders
11/10/2009	CA2378792C Aminothiazole derivatives and their use as crf receptor ligands
11/10/2009	CA2353460C Carboxylic acids and carboxylic acid isosteres of n-heterocyclic compounds
11/05/2009	WO2009135135A2 Fibromodulin formulation for reducing corneal scarring
11/05/2009	WO2009134711A1 Humanized anti-factor d antibodies and uses thereof
11/05/2009	WO2009133951A1 Anti-perspiration antigen monoclonal antibody
11/05/2009	WO2009133831A1 Phenylpropionic acid derivative and use thereof
11/05/2009	WO2009133701A1 Phenylimidazole derivative and therepeutic and/or prophylactic agent for retinal/choroidal disorder
11/05/2009	WO2009133552A2 Methods of treating ophthalmic disorders
11/05/2009	WO2009132986A1 Imidazolidinone derivatives as 11b-hsd1 inhibitors
11/05/2009	WO2009105534A3 Ophthalmic nsaids as adjuvants
11/05/2009	WO2009084069A4 Ocular solution with organic lycopene
11/05/2009	US20090275641 RNAi-Mediated Inhibition of RHO Kinase for Treatment of Ocular Disorders
11/05/2009	US20090275611 Compounds Which Modulate The CB2 Receptor
11/05/2009	US20090275580 3-spiroindolin-2-one derivatives, preparation and therapeutic use thereof
11/05/2009	US20090275579 3-spiroindolin-2-one derivatives, preparation and therapeutic use thereof
11/05/2009	US20090275522 Novel Compounds
11/05/2009	US20090274717 Genes and proteins, and their use
11/05/2009	US20090274695 Inhibition of urokinase-type plasminogen activator (uPA) activity
11/05/2009	US20090274632 Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof
11/05/2009	CA2720853A1 Humanized anti-factor d antibodies and uses thereof
11/04/2009	EP2112927A2 Method for treatment of overfiltering and leaking blebs with sterile talc
11/04/2009	EP1542716B1 Growth hormone releasing peptides
11/04/2009	EP1432700B1 Spiro-hydantoin compounds useful as anti-inflammatory agents
11/04/2009	EP1311488B1 Substituted imidazoles as tafia inhibitors
11/04/2009	EP1204430B1 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
11/03/2009	US7612238 Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases
11/03/2009	US7612115 Citric acid, polyethylene glycol, and ofloxacin; low gelation temperatures; bioavailability
11/03/2009	US7612094 Tri-substituted heteroaryls and methods of making and using the same
11/03/2009	US7612092 Nitrogen-containing aromatic derivatives
11/03/2009	US7612083 Urea substituted imidazoquinoline ethers
11/03/2009	US7612047 Degradation-resistant mononucleoside phosphate compounds
11/03/2009	CA2447924C Olopatadine formulations for topical administration
11/03/2009	CA2353133C Treatment of disorders secondary to organic impairments
10/2009
10/29/2009	WO2009132253A1 Use of epothelone d in treating tau-associated diseases including alzheimer's disease
10/29/2009	WO2009132228A1 Chitosan-containing protective composition
10/29/2009	WO2009132226A1 Thiolated chitosan gel
10/29/2009	WO2009132093A2 Substituted arylcyclopentenes as therapeutic agents
10/29/2009	WO2009132088A1 Substituted gamma lactams as therapeutic agents
10/29/2009	WO2009132087A1 Thiophene derivatives useful as ocular hypotensive agents
10/29/2009	WO2009132085A1 Substituted arylcyclopentenes as prostaglandin ep2 agonists
10/29/2009	WO2009132050A2 Auris formulations for treating otic diseases and conditions
10/29/2009	WO2009131940A1 Limk2 inhibitors, compositions comprising them, and methods of their use
10/29/2009	WO2009131850A2 Pai-1 expression and activity inhibitors for the treatment of ocular disorders
10/29/2009	WO2009131673A1 Targeted treatment for subjects with estrogen receptor negative and progesterone receptor negative breast cancers
10/29/2009	WO2009131171A1 Novel five-membered ring compound
10/29/2009	WO2009131170A1 Five-membered ring compound
10/29/2009	WO2009131164A1 Eye-drop preparation and use thereof
10/29/2009	WO2009131065A1 Long-chain fatty acid elongation enzyme inhibitor comprising arylsulfonyl derivative as active ingredient
10/29/2009	WO2009130296A2 Anti-alk1 antibodies and uses thereof
10/29/2009	WO2009129859A1 Compositions and methods for maintaining, strengthening, improving, or promoting eye health
10/29/2009	WO2009129726A1 Nitrone compounds, process of preparation thereof, and use thereof in medicament manufacture
10/29/2009	WO2009094466A3 Contact lenses for extended release of bioactive agents containing diffusion attenuators
10/29/2009	WO2009065022A3 Low density lipoprotein receptor-mediated sirna delivery
10/29/2009	US20090270474 Therapeutic Agent for Keratoconjunctival Disorder
10/29/2009	US20090270472 Method to use oxymetazoline to interrupt the development of the common cold syndrome
10/29/2009	US20090270458 Method of treating of demyelinating diseases or conditions
10/29/2009	US20090270395 EP4 Receptor Agonist, Compositions and Methods Thereof
10/29/2009	US20090270368 Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
10/29/2009	US20090270345 Polymeric artificial tear system
10/29/2009	US20090270315 Method of inhibiting angiogenesis by using ephrin b2
10/29/2009	US20090269410 Inhibition of Neovascularization by Cerium Oxide Nanoparticles
10/29/2009	US20090269369 Ophthalmic Composition Comprising Xanthan Gum and Glucose
10/29/2009	US20090269349 Antigenic polypeptides
10/29/2009	CA2722529A1 Substituted gamma lactams as therapeutic agents
10/29/2009	CA2722456A1 Substituted arylcyclopentenes as prostaglandin ep2 agonists
10/29/2009	CA2722403A1 Substituted arylcyclopentenes as therapeutic agents
10/29/2009	CA2722371A1 Use of epothelone d in treating tau-associated diseases including alzheimer's disease
10/29/2009	CA2722312A1 Thiophene derivatives useful as ocular hypotensive agents
10/29/2009	CA2722075A1 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient
10/29/2009	CA2722041A1 Novel five-membered ring compound

1 ... 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 ... 531